LithiumBank Resources

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 746.06
-9.40 -1.24
142,676
105.72M
US$ 78.870B
US$ 171.17
-4.76 -2.71
1.77M
405.45M
US$ 69.400B
US$ 159.69
-7.02 -4.21
650,790
242.52M
US$ 38.730B
US$ 6.31
0.13 2.10
782,559
684.79M
US$ 4.320B
US$ 11.47
-0.44 -3.69
783,617
281.58M
US$ 3.230B
US$ 17.46
-0.26 -1.47
578,122
159.67M
US$ 2.790B
US$ 37.01
-1.51 -3.92
240,134
58.53M
US$ 2.170B
US$ 1.71
-0.10 -5.28
7.77M
1.19B
US$ 2.030B
US$ 76.85
1.07 1.41
52,824
24.91M
US$ 1.910B
US$ 3.40
-0.06 -1.73
242,781
488.43M
US$ 1.660B
US$ 9.07
-0.04 -0.44
419,839
159.52M
US$ 1.450B
US$ 9.38
0.21 2.29
290,684
147.19M
US$ 1.380B
US$ 26.91
-2.20 -7.56
592,761
51.39M
US$ 1.380B
US$ 32.00
-2.16 -6.32
58,335
42.85M
US$ 1.370B
US$ 33.24
-0.50 -1.48
688,771
40.02M
US$ 1.330B
US$ 15.94
0.29 1.85
198,978
61.23M
US$ 976.010M
US$ 32.10
-0.31 -0.96
139,901
29.40M
US$ 943.740M
US$ 1.00
0.00 0.00
3.22M
851.56M
US$ 851.560M
US$ 19.00
-0.47 -2.41
109,952
43.82M
US$ 832.580M
US$ 33.00
-0.02 -0.06
12,844
24.87M
US$ 820.710M
US$ 4.23
-0.12 -2.76
218,097
188.83M
US$ 798.750M
US$ 13.27
-0.40 -2.93
173,536
55.66M
US$ 738.610M
US$ 8.53
-1.05 -10.96
4.63M
76.02M
US$ 648.620M
US$ 10.51
0.03 0.29
52,548
61.54M
US$ 646.790M
US$ 2.19
0.19 9.50
13.79M
290.14M
US$ 635.410M
US$ 13.73
-0.47 -3.31
48,018
42.67M
US$ 585.860M
US$ 1.82
-0.01 -0.55
1.84M
308.24M
US$ 561.000M
US$ 7.32
-0.17 -2.27
679,458
73.68M
US$ 539.340M
US$ 16.10
-1.41 -8.06
25,912
33.43M
US$ 538.060M
US$ 10.33
-0.46 -4.26
142,470
42.58M
US$ 440.000M
US$ 2.00
0.06 2.84
883,790
217.79M
US$ 434.490M
US$ 8.39
-0.44 -4.98
56,251
49.30M
US$ 413.630M
US$ 8.21
-0.26 -3.07
57,453
48.54M
US$ 398.520M
US$ 30.13
0.21 0.70
524
12.97M
US$ 390.790M
US$ 0.72
-0.05 -6.47
164,550
515.34M
US$ 371.040M
US$ 3.96
0.03 0.80
46,061
89.90M
US$ 356.130M
US$ 16.47
0.28 1.73
110,009
20.97M
US$ 345.380M
US$ 14.00
-0.98 -6.54
305,345
23.63M
US$ 330.820M
US$ 6.72
-0.05 -0.74
39,316
47.77M
US$ 321.010M
US$ 2.13
-0.04 -1.62
90,262
148.90M
US$ 316.410M
US$ 3.04
-0.20 -6.17
128,220
103.12M
US$ 313.480M
US$ 8.02
0.23 2.95
279
35.86M
US$ 287.420M
US$ 13.34
-0.05 -0.37
23,462
20.89M
US$ 278.670M
US$ 8.11
-0.04 -0.49
374,621
32.95M
US$ 267.220M
US$ 2.51
0.11 4.38
256,818
92.59M
US$ 231.940M
US$ 1.96
-0.17 -7.98
124,460
109.92M
US$ 215.440M
US$ 3.52
-0.51 -12.66
27,157
60.94M
US$ 214.510M
US$ 1.93
-0.01 -0.52
36,066
109.62M
US$ 211.570M
US$ 3.57
-0.02 -0.56
41,370
58.08M
US$ 207.350M
US$ 6.66
-0.11 -1.62
15,212
29.04M
US$ 193.410M
US$ 0.20
-0.008 -3.94
5.51M
979.89M
US$ 191.080M
US$ 0.37
-0.03 -7.73
820,416
496.25M
US$ 185.350M
US$ 4.51
-0.21 -4.45
70,995
37.29M
US$ 168.180M
US$ 6.28
0.11 1.78
23,872
25.78M
US$ 161.900M
US$ 4.91
-0.44 -8.22
38,842
32.13M
US$ 157.760M
US$ 6.01
-0.08 -1.31
34,594
25.27M
US$ 151.870M
US$ 1.21
-0.09 -6.59
87,682
123.20M
US$ 148.460M
US$ 5.63
-0.48 -7.86
31,058
26.32M
US$ 148.180M
US$ 7.21
-0.69 -8.73
45,502
19.71M
US$ 142.110M
US$ 1.87
-0.05 -2.60
54,058
72.06M
US$ 134.750M
US$ 3.29
0.10 3.13
73,279
39.90M
US$ 131.270M
US$ 6.77
-0.06 -0.88
105,735
18.74M
US$ 126.870M
US$ 1.08
0.08 8.01
364,721
105.50M
US$ 113.950M
US$ 1.67
-0.04 -2.06
85,222
68.29M
US$ 113.700M
US$ 7.64
0.06 0.79
849
14.64M
US$ 111.850M
US$ 5.31
-0.15 -2.75
10,845
19.43M
US$ 103.170M
US$ 11.98
-0.37 -3.00
14,785
8.10M
US$ 97.010M
US$ 2.30
-0.12 -4.96
103,723
41.28M
US$ 94.940M
US$ 5.94
0.13 2.24
100,809
15.91M
US$ 94.510M
US$ 2.57
0.00 0.00
0
35.96M
US$ 92.420M
US$ 6.78
-0.47 -6.48
35,284
13.34M
US$ 90.450M
US$ 2.38
0.15 6.73
141,073
36.26M
US$ 86.300M
US$ 1.97
-0.12 -5.96
84,185
43.49M
US$ 85.480M
US$ 2.53
0.00 0.00
0
30.40M
US$ 76.910M
US$ 3.29
-0.11 -3.10
5,799
23.34M
US$ 76.670M
US$ 2.96
-0.04 -1.33
4,621
24.96M
US$ 73.880M
US$ 1.19
0.04 3.48
25,268
59.34M
US$ 70.610M
US$ 1.62
-0.08 -4.71
30,944
43.11M
US$ 69.840M
US$ 2.79
-0.11 -3.79
36,524
23.74M
US$ 66.230M
US$ 4.78
0.03 0.63
3,006
13.59M
US$ 64.960M
US$ 0.86
0.07 8.81
69,238
66.94M
US$ 57.560M
US$ 1.38
-0.04 -2.82
59,319
41.35M
US$ 57.060M
US$ 4.40
-0.25 -5.38
12,859
12.70M
US$ 55.880M
US$ 3.93
-0.09 -2.12
76,211
13.57M
US$ 53.260M
US$ 1.41
-13.88 -90.78
82,623
37.28M
US$ 52.560M
US$ 1.14
0.05 4.59
17,071
43.58M
US$ 49.680M
US$ 2.02
0.00 0.00
16,239
24.42M
US$ 49.330M
US$ 5.71
0.01 0.18
2,877
8.58M
US$ 48.990M
US$ 1.33
0.03 2.28
9,630
35.17M
US$ 46.780M
US$ 1.46
0.03 2.10
26,790
30.60M
US$ 44.680M
US$ 3.50
-0.23 -6.17
17,629
12.65M
US$ 44.280M
US$ 0.93
-0.02 -2.13
8,381
47.48M
US$ 44.160M
US$ 2.33
-0.11 -4.66
48,937
18.75M
US$ 43.620M
US$ 0.44
-0.04 -7.57
349,658
92.58M
US$ 40.350M
US$ 0.22
-0.02 -8.34
812,752
186.62M
US$ 40.180M
US$ 3.22
-0.07 -2.13
12,402
11.88M
US$ 38.250M
US$ 0.48
0.00 0.00
0
78.85M
US$ 37.830M
US$ 1.32
-0.08 -5.72
113,609
28.56M
US$ 37.700M
US$ 1.67
0.03 1.83
52,909
21.75M
US$ 36.320M
US$ 1.42
-0.02 -1.40
7,545
25.26M
US$ 35.870M
US$ 0.04
0.00 0.00
40,174
1.01B
US$ 35.350M
US$ 0.84
-0.04 -4.10
67,298
38.10M
US$ 32.000M
US$ 0.49
-0.02 -4.25
80,808
63.70M
US$ 31.270M
US$ 0.10
0.003 3.23
690,814
317.06M
US$ 30.440M
US$ 2.23
-0.77 -25.72
2.57M
13.47M
US$ 30.020M
US$ 2.49
-0.27 -9.79
432,558
11.78M
US$ 29.330M
US$ 1.45
-0.06 -3.97
5,737
19.85M
US$ 28.780M
US$ 1.11
-0.12 -9.76
85,972
25.65M
US$ 28.470M
US$ 1.48
-0.12 -7.50
8,000
19.17M
US$ 28.370M
US$ 0.51
-0.06 -11.27
33,827
53.98M
US$ 27.530M
US$ 3.34
-0.21 -5.92
4,970
7.82M
US$ 26.120M
US$ 0.80
-0.03 -3.31
8,636
32.66M
US$ 26.110M
US$ 0.84
0.0001 0.01
1,937
29.96M
US$ 25.170M
US$ 0.69
-0.02 -3.08
126,900
36.13M
US$ 25.050M
US$ 0.88
-0.07 -7.28
264,530
26.14M
US$ 23.020M
US$ 1.99
-0.06 -2.93
3,115
11.53M
US$ 22.940M
US$ 1.02
0.04 4.07
7,456
21.89M
US$ 22.330M
US$ 0.45
-0.02 -4.78
1.09M
49.32M
US$ 22.100M
US$ 0.32
-0.04 -12.06
300
64.24M
US$ 20.810M
US$ 3.57
-0.05 -1.38
73,676
5.82M
US$ 20.780M
US$ 0.19
0.0051 2.72
3,300
97.06M
US$ 18.680M
US$ 0.05
0.0024 5.04
194,320
369.70M
US$ 18.480M
US$ 3.51
-0.16 -4.43
84,822
5.15M
US$ 18.060M
US$ 0.18
0.03 19.20
168,080
96.89M
US$ 17.320M
US$ 2.90
-0.03 -1.02
3,461
5.95M
US$ 17.260M
US$ 0.94
-0.06 -6.00
34,371
18.15M
US$ 17.060M
US$ 0.41
-0.02 -5.39
39,794
41.89M
US$ 17.050M
US$ 0.07
0.00 0.00
0
239.53M
US$ 16.310M
US$ 0.05
0.00 0.00
0
318.30M
US$ 15.920M
US$ 0.12
-0.0057 -4.42
2.05M
125.28M
US$ 15.450M
US$ 0.28
0.00 0.00
0
54.50M
US$ 15.300M
US$ 1.70
-0.10 -5.56
60,320
8.91M
US$ 15.150M
US$ 1.06
-0.11 -9.40
22,784
13.93M
US$ 14.770M
US$ 1.29
-0.08 -5.84
415,774
11.37M
US$ 14.670M
US$ 0.34
0.0068 2.04
55,624
39.22M
US$ 13.330M
US$ 0.24
-0.03 -9.36
4.25M
52.40M
US$ 12.690M
US$ 0.29
-0.0096 -3.21
100
41.99M
US$ 12.160M
US$ 1.76
-0.04 -2.22
100
6.69M
US$ 11.770M
US$ 0.88
0.03 4.00
1,570
12.65M
US$ 11.190M
US$ 1.45
-0.03 -2.09
4,425
7.43M
US$ 10.770M
US$ 3.49
0.39 12.58
26,774
2.94M
US$ 10.260M
US$ 0.04
-0.0035 -7.25
82,592
224.63M
US$ 10.060M
US$ 0.15
0.00 0.00
0
65.06M
US$ 9.760M
US$ 1.79
0.01 0.56
34,025
5.12M
US$ 9.160M
US$ 0.23
-0.0033 -1.43
51,801
40.24M
US$ 9.120M
US$ 0.40
-0.0084 -2.06
21,260
22.71M
US$ 9.060M
US$ 0.14
-0.0034 -2.41
769,057
63.82M
US$ 8.790M
US$ 0.03
0.00 0.00
0
333.40M
US$ 8.600M
US$ 0.12
0.00 0.00
0
72.14M
US$ 8.580M
US$ 0.25
0.00 0.00
0
34.19M
US$ 8.540M
US$ 2.98
-0.07 -2.30
20,609
2.73M
US$ 8.140M
US$ 2.08
-0.20 -8.59
539,464
2.84M
US$ 5.890M
US$ 0.21
-0.01 -4.64
739,543
28.15M
US$ 5.780M
US$ 0.14
-0.002 -1.40
2.07M
39.33M
US$ 5.550M
US$ 1.95
-0.05 -2.50
1,285
2.83M
US$ 5.520M
US$ 0.41
-0.0099 -2.36
16,953
13.39M
US$ 5.490M
US$ 0.42
-0.0001 -0.02
46,234
12.90M
US$ 5.420M
US$ 0.42
-0.0063 -1.48
87,396
12.90M
US$ 5.420M
US$ 0.12
0.0002 0.17
1.45M
46.09M
US$ 5.360M
US$ 3.62
-0.08 -2.16
13,422
1.32M
US$ 4.780M
US$ 1.66
-0.15 -8.06
28,758
2.87M
US$ 4.750M
US$ 0.05
0.00 0.00
0
88.23M
US$ 4.670M
US$ 0.06
0.00 0.00
1,287
66.67M
US$ 4.130M
US$ 0.11
0.00 0.00
0
36.93M
US$ 4.040M
US$ 2.21
0.02 1.13
1,960
1.67M
US$ 3.700M
US$ 0.02
-0.0016 -6.08
9,000
132.63M
US$ 3.280M
US$ 0.03
0.0013 4.96
44,459
111.14M
US$ 3.060M
US$ 0.04
0.00 0.00
0
71.27M
US$ 2.780M
US$ 0.05
0.00 0.00
0
51.46M
US$ 2.650M
US$ 0.40
0.00 0.00
35,159
6.33M
US$ 2.510M
US$ 0.29
0.0004 0.14
538,066
8.33M
US$ 2.410M
US$ 0.02
0.00 0.00
0
88.94M
US$ 1.640M
US$ 0.04
0.0099 32.89
2,000
36.50M
US$ 1.460M
US$ 0.01
0.0019 17.12
74,334
97.28M
US$ 1.260M
US$ 0.02
0.00 0.00
0
45.93M
US$ 827K
US$ 0.00575
0.00 0.00
0
120.69M
US$ 694K
US$ 0.0058
0.00 0.00
7,100
103.35M
US$ 599K
US$ 0.68
-0.02 -2.84
39,217
-
US$ -
US$ 2.10
-0.10 -4.33
19,862
-
US$ -

BioTech Stock News


Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology... Read more


Defence Therapeutics Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies

Vancouver, British Columbia--(Newsfile Corp. - December 6, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOXTM molecule.... Read more


Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

ROCKVILLE, Md., Dec. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript discussing prostate cancer cell lines derived from African American men for precision medicine.... Read more


RedHill Biopharma Closes $8.0 Million Underwritten Public Offering

TEL AVIV, Israel and RALEIGH, N.C., Dec. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of an underwritten public offering with gross proceeds to the Company of approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company. The offering... Read more


HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analysis of the 203 subjects enrolled in the run-in cohort of NEST-IN1 (Norovirus Efficacy and Safety Trial for INfants), the company’s ongoing Phase 2b trial for HIL-214,... Read more


Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product  SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose,... Read more


Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

LP352 exhibited a strong correlation between plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) concentration, which increased in a dose-dependent and consistent manner LP352 demonstrated early quantitative electroencephalogram (qEEG) changes, and sustained effects on qEEG activity after continuous dosing in a dose-dependent manner indicating receptor engagement Favorable safety... Read more


Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate) 5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cycles Patients with CR observed across multiple NHL histologies, including LBCL Consolidation dosing... Read more


Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic...

Hematopoietic Stem Cell Transplantation (HCT) from Unrelated Donors is a Component of the Treatment Protocol for Several Hematologic Malignancies GvHD Complicates Treatment and Limits the Success of Engraftment after HCT In addition to GvHD, Tonix is Developing TNX-1500 for Prophylaxis of Organ Transplant Rejection and Treatment of Autoimmune Disorders Phase 1 Study of TNX-1500 is Expected to... Read more


Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment... Read more


EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

Submission is EQRx’s first to European Medicines Agency Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to... Read more


Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions

BOSTON, Dec. 2, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with Bayer CropScience LP ("Bayer") on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen... Read more


BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs like SPDR S&P Biotech (NYSEARCA: XBI) (“XBI”) and iShares Biotechnology (NASDAQ: IBB) (“IBB”) are bringing a lot of awareness and attention to the field for investors to get excited about. BriaCell... Read more


Voyageur Pharmaceuticals Announces Equity Incentive Compensation

Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Units ("DSUs") to directors pursuant to its fixed 10% equity incentive compensation plan adopted by the Company following receipt of shareholder approval on June 28, 2021 (the "Plan"). Each DSU represents... Read more


RedHill Biopharma Prices $8.0 Million Underwritten Public Offering

TEL AVIV, Israel, and RALEIGH, N.C., Dec. 2, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company. The... Read more


ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early...

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determine Next Steps NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)... Read more


Roivant Sciences and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis   RVT-3101 is currently being evaluated in a large global Phase 2b study (TUSCANY-2) with final results expected in 1H 2023 BASEL, Switzerland and LONDON... Read more


Regeneron Pharmaceuticals ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced non-small cell lung cancer TARRYTOWN, N.Y., Dec. 1, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology... Read more


AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify... Read more


FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to... Read more


Regeneron Pharmaceuticals: Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

If approved, Evkeeza would be the first and only treatment of its kind to help children as young as 5 years old control dangerously high levels of LDL cholesterol caused by homozygous familial hypercholesterolemia TARRYTOWN, N.Y., Nov. 30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for... Read more


BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech In addition to these programs, BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules Ryvu will... Read more


ImmunoPrecise Antibodies Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage... Read more


Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect

Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply Disruption Adzenys XR-ODT is the Only FDA-Approved, Extended-Release, Orally Disintegrating Tablet Formulation of Amphetamine Adzenys XR-ODT Continues to be Available as an... Read more


TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application to the U.S. Food and Drug Administration (FDA) for a planned First-in-Human Phase 0 clinical trial. The planned clinical... Read more


Check-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

ISFIYA, Israel, Nov. 30, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided... Read more


Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130. Philip... Read more


Nova Mentis Life Science Submits Phase II A Psilocybin Clinical Trial Application to Health Canada

Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is... Read more


Irwin Naturals Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it reached a binding, arms-length, agreement to acquire Serenity Health, LLC in Louisville, Kentucky, on November 25, 2022. The move continues Irwin’s national ketamine clinic rollup strategy that has seen the Company move quickly toward... Read more


Revive Therapeutics Announces Offering of Up to $5 Million

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a “Unit”), at a price of $0.15 per Unit; (the “Offering”). The Offering is being led by EMD Financial Inc. Each Unit shall be comprised... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS